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Abstract	  
Clozapine,	  a	  current	  schizophrenic	  medication,	  can	  adversely	  affect	  a	  patient’s	  immune	  system.	  
Clozapine	  causes	  agranulocytosis	  (loss	  of	  white	  blood	  cells)	  in	  some	  patients.	  The	  mechanism	  underlying	  
clozapine-­‐induced	  agranulocytosis	  is	  not	  well	  understood.	  Our	  working	  hypothesis	  is	  that	  clozapine	  
reacts	  with	  hydrogen	  peroxide	  (H2O2)	  within	  granulocytes,	  generating	  a	  toxic	  product	  that	  kills	  the	  
immune	  cells.	  We	  have	  developed	  an	  assay	  in	  the	  model	  organism	  –	  Saccharomyces	  cerevisiae	  to	  
understand	  the	  effects	  of	  clozapine.	  We	  produced	  11	  reproducibly	  repeated	  trials	  that	  resulted	  in	  a	  
negative	  correlation	  between	  the	  concentration	  of	  clozapine	  and	  yeast	  cell	  density.	  The	  establishment	  
of	  a	  reliable	  assay	  for	  clozapine-­‐induced	  cell	  death	  and	  the	  determination	  of	  the	  MIC50	  of	  clozapine	  for	  
yeast	  cells	  may	  contribute	  to	  future	  S.	  cerevisiae	  genomic	  screens,	  and	  the	  repeated	  dose	  dependent	  
inhibition	  of	  yeast	  cell	  growth	  by	  clozapine,	  in	  the	  presence	  of	  H2O2,	  indicates	  that	  yeast	  cells	  can	  indeed	  
serve	  as	  a	  model	  for	  understanding	  agranulocytosis	  in	  the	  population	  of	  patients	  treated	  with	  clozapine.	  
Introduction	  
Rationale	  and	  Project	  Summary	  
Clozapine	  is	  currently	  the	  most	  effective	  drug	  for	  treating	  schizophrenia,	  which	  is	  a	  disease	  with	  
pervasive	  impacts	  on	  our	  society.	  Clozapine	  is	  especially	  important	  as	  the	  drug	  of	  choice	  when	  treating	  
refractory	  (resistant	  to	  treatment)	  schizophrenia,	  which	  represents	  one-­‐quarter	  of	  the	  total	  
schizophrenia	  diagnoses.	  In	  addition,	  clozapine	  is	  currently	  being	  researched	  for	  its	  potential	  role	  in	  
treating	  other	  disorders,	  such	  as	  psychotic	  symptoms	  occurring	  in	  patients	  with	  dementia	  of	  the	  Lewy-­‐
body-­‐type,	  intractable	  chronic	  insomnia,	  and	  schizoid	  personality	  disorder.	  Unfortunately,	  clozapine	  has	  
been	  relegated	  to	  third-­‐line	  use,	  even	  though	  it	  could	  be	  more	  effective	  than	  other	  drugs,	  due	  to	  its	  
potentially	  lethal	  side	  effects,	  mainly	  agranulocytosis	  and	  myocarditis.	  Although	  the	  mechanism	  of	  
clozapine-­‐induced	  agranulocytosis	  is	  still	  unknown	  there	  are	  two	  main	  hypotheses	  and	  these	  are	  the	  
immune	  and	  toxic	  mechanisms.	  The	  toxic	  mechanism	  hypothesis	  proposes	  that	  some	  toxic	  product	  or	  
aspect	  of	  clozapine	  itself	  causes	  the	  death	  of	  white	  blood	  cells.	  Whereas,	  the	  immune	  hypothesis	  
proposes	  that	  it	  is	  the	  interaction	  between	  the	  H2O2	  produced	  by	  white	  blood	  cells	  and	  clozapine	  that	  
then	  kills	  white	  blood	  cells.	  Researchers	  are	  trying	  to	  understand	  the	  mechanism	  in	  hopes	  of	  producing	  a	  
safer	  version	  of	  clozapine	  that	  does	  not	  cause	  agranulocytosis.	  (Wahlbeck,	  2007)	  
The	  clozapine	  mechanism	  of	  symptom	  relief	  is	  proposed	  to	  be	  preferential	  binding	  to	  serotonin	  5-­‐
HT2	  and	  dopamine	  D4	  receptors	  relative	  to	  dopamine	  D2	  receptors,	  (Sharafi,	  2005).	  Clozapine,	  which	  was	  
first	  introduced	  in	  1971,	  is	  a	  tricyclic	  dibenzodiazepine	  derivative,	  8-­‐chloro-­‐11-­‐(4-­‐methyl-­‐1-­‐piperazinyl)-­‐
5H-­‐dibenzo	  [1,4]	  diazepine;	  Figure	  1	  shows	  its	  structural	  formula,	  (WebMD,	  2009). 
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Figure	  1.	  The	  Structural	  Formula	  of	  Clozapine	  
 
There	  are	  several	  other	  atypical	  antipsychotics,	  but	  clozapine	  is	  by	  far	  the	  best	  at	  bringing	  about	  
symptom	  relief	  to	  the	  large	  percentage	  of	  sufferers	  of	  refractory	  schizophrenia.	  In	  fact,	  clozapine	  is	  
often	  the	  only	  drug	  that	  brings	  any	  relief	  at	  all	  to	  these	  patients.	  Clozapine	  is	  more	  effective	  than	  other	  
antipsychotic	  drugs	  in	  reducing	  the	  positive	  symptoms	  and	  the	  harder	  to	  treat	  negative	  symptoms	  of	  
schizophrenia,	  eliminating	  the	  dyscognitive	  effect,	  motor	  adverse	  effects	  and	  extrapyramidal	  side	  effects	  
seen	  with	  other	  psychoactive	  drugs,	  fostering	  social	  rehabilitation,	  reducing	  the	  propensity	  for	  
substance	  abuse,	  prolonging	  the	  time	  to	  suicidal	  attempt,	  and	  producing	  clinically	  meaningful	  
improvements	  and	  postponing	  relapse,	  (Lee,	  1998	  and	  McEvoy,	  2006).	  This	  may	  explain	  why	  patients	  
are	  generally	  more	  satisfied	  with	  clozapine	  treatment	  than	  with	  typical	  antipsychotic	  treatment.	  
(Wahlbeck,	  2007)	  
Due	  to	  the	  fact	  that	  it	  is	  known	  to	  cause	  agranulocytosis	  in	  approximately	  1%	  of	  patients,	  clozapine	  
was	  restricted	  entirely	  by	  the	  US	  Food	  and	  Drug	  Administration	  (FDA)	  for	  a	  period	  of	  time,	  and	  is	  
currently	  only	  allowed	  for	  treating	  patients	  as	  a	  last	  resort.	  Even	  when	  clozapine	  is	  allowed	  for	  
treatment	  after	  meeting	  the	  strict	  guidelines	  for	  the	  last	  resort	  drug,	  the	  patient	  must	  undergo	  weekly	  
mandated	  blood	  tests	  to	  detect	  leukopenia;	  this	  can	  prove	  difficult	  or	  impossible	  for	  severely	  
schizophrenic	  patients	  and	  their	  families	  to	  adhere	  to.	  Ultimately,	  refractory	  schizophrenics	  are	  left	  with	  
no	  satisfactory	  solution,	  and	  patients	  unable	  to	  qualify	  for	  clozapine	  are	  being	  treated	  with	  drugs	  that	  
may	  not	  be	  providing	  them	  with	  as	  effective	  symptom	  relief	  as	  clozapine	  could.	  
Establishing	  that	  clozapine	  and	  its	  mechanism	  of	  white	  blood	  cell	  death	  can	  be	  studied	  in	  the	  model	  
organism	  S.	  cerevisiae,	  would	  allow	  for	  improved	  and	  expanded	  research	  to	  determine	  the	  mechanism	  
of	  action	  behind	  clozapine-­‐induced	  white	  blood	  cell	  death.	  Being	  able	  to	  study	  clozapine	  and	  
agranulocytosis	  in	  a	  system	  other	  than	  in-­‐vitro	  agranulocytes	  is	  especially	  significant	  when	  that	  system	  is	  
S.	  cerevisiae,	  since	  its	  entire	  genome	  has	  been	  sequenced	  and	  novel	  experiments	  could	  be	  conducted	  
that	  would	  be	  impossible	  with	  agranulocytes.	  If	  clozapine’s	  negative	  side-­‐effects,	  particularly	  
agranulocytosis,	  could	  be	  understood	  and	  overcome,	  this	  effective	  antipsychotic	  could	  provide	  much	  
needed	  relief	  to	  millions	  of	  schizophrenic	  patients.	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Background	  on	  Schizophrenia	  
Schizophrenia,	  one	  of	  the	  most	  widespread	  psychiatric	  disorders,	  is	  a	  chronic,	  severe,	  and	  disabling	  
brain	  disorder.	  It	  is	  defined	  as	  a	  psychiatric	  diagnosis	  that	  describes	  a	  mental	  disorder	  characterized	  by	  
abnormalities	  in	  the	  perception	  or	  expression	  of	  reality.	  (American	  Psychiatric	  Association,	  2000)	  Simply	  
put,	  schizophrenia	  causes	  patients	  to	  lose	  touch	  with	  reality,	  because	  they	  are	  often	  unable	  to	  make	  
sense	  of	  the	  signals	  they	  receive	  from	  the	  world	  around	  them.	  Schizophrenia	  is	  marked	  by	  severely	  
impaired	  reasoning	  and	  emotional	  instability,	  and	  it	  can	  often	  cause	  violent	  behavior.	  Schizophrenics	  
often	  believe	  people,	  objects	  and	  events	  to	  be	  very	  different	  from	  what	  they	  really	  are.	  If	  untreated	  or	  
refractory	  to	  treatment,	  most	  schizophrenics	  gradually	  withdraw	  from	  the	  outside	  world	  or	  are	  unable	  
to	  function	  within	  it.	  (Tsuang,	  1997)	  
Prevalence	  and	  Impact	  
Schizophrenia	  is	  truly	  a	  debilitating	  disease	  that	  effects	  many	  people	  and	  is	  a	  major	  public	  health	  
problem	  with	  pervasive	  impact	  on	  our	  society.	  It	  affects	  approximately	  24	  million	  people	  worldwide	  and	  
more	  than	  two	  million	  Americans	  in	  a	  given	  year,	  (Sharafi,	  2005).	  Estimates	  reach	  as	  high	  as	  1%	  of	  the	  
world's	  population	  being	  affected,	  (Tsuang,	  1997).	  A	  2002	  systematic	  review	  of	  18	  prevalence	  and	  eight	  
incidence	  studies,	  which	  met	  stringent	  eligibility	  criteria	  for	  the	  review,	  found	  a	  lifetime	  prevalence	  rate	  
of	  0.55%,	  (Goldner,	  2002).	  Approximately,	  half	  of	  all	  patients	  in	  psychiatric	  hospitals	  are	  diagnosed	  with	  
schizophrenia	  and	  they	  may	  occupy	  as	  many	  as	  one	  quarter	  of	  the	  world's	  hospital	  beds,	  (Tsuang,	  1997).	  
Not	  only	  are	  the	  many	  sufferers	  of	  schizophrenia	  affected,	  but	  their	  families	  are	  as	  well.	  Families	  of	  
schizophrenics	  struggle	  with	  a	  sense	  of	  loss	  and	  the	  demanding	  lifestyle	  imposed	  by	  caring	  for	  loved	  
ones	  dealing	  with	  the	  disorder.	  Even	  books	  and	  movies,	  such	  as	  “A	  Beautiful	  Mind,”	  have	  portrayed	  the	  
often	  devastating	  cultural	  effects	  of	  schizophrenia.	  (Pescosolido,	  1999)	  
Epidemiology	  
Schizophrenia	  affects	  people	  of	  all	  ages,	  races,	  genders,	  social	  classes,	  levels	  of	  education,	  or	  ethnic	  
backgrounds,	  (Tsuang,	  1997).	  It	  occurs	  equally	  in	  males	  and	  females,	  although	  it	  typically	  appears	  earlier	  
in	  men.	  The	  peak	  ages	  of	  onset	  are	  20–28	  years	  for	  males	  and	  26–32	  years	  for	  females.	  (Castel,	  1991)	  
Most	  patients	  are	  diagnosed	  in	  their	  late	  teens	  or	  early	  twenties,	  but	  the	  disorder	  can	  appear	  at	  any	  
time	  in	  a	  person's	  life	  and	  it	  has	  even	  been	  reported	  in	  children	  as	  young	  as	  five	  years	  of	  age,	  (Tsuang,	  
1997).	  It	  also	  occurs	  all	  over	  the	  world	  at	  similar	  rates.	  However,	  the	  prevalence	  of	  schizophrenia	  does	  
vary	  among	  countries,	  within	  them	  and	  at	  the	  local	  level.	  (Kirkbride,	  2006)	  For	  example,	  interesting	  
epidemiology	  studies	  have	  indicated	  a	  correlation	  between	  urban	  environments	  and	  schizophrenia	  even	  
after	  controlling	  for	  factors	  such	  as	  drug	  use,	  ethnic	  group	  and	  size	  of	  social	  group,	  (Van	  Os,	  2004).	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Symptoms	  and	  Prognosis	  
Schizophrenia’s	  main	  debilitating	  effect	  is	  the	  deterioration	  of	  proper	  cognition,	  or	  information	  
processing.	  It	  also	  usually	  contributes	  to	  chronic	  problems	  with	  behavior	  and	  emotion,	  such	  as	  paranoia,	  
avolition	  (lack	  of	  motivation),	  and	  apathy.	  Patients	  exhibit	  lifelong	  deficits	  with	  the	  majority	  of	  
symptoms	  described	  by	  ‘the	  four	  As’:	  	  
1.)	  Association	  disturbances	  
2.)	  Ambivalence	  
3.)	  Affect	  disturbances	  
4.)	  Autism	  	  
It	  was	  Eugen	  Bleuler,	  an	  influential	  Swiss	  psychiatrist,	  who	  in	  1908	  proposed	  the	  four	  A’s	  to	  describe	  
the	  main	  symptoms	  of	  schizophrenia	  and	  in	  1911	  introduced	  the	  term	  schizophrenia	  to	  replace	  
dementia	  praecox.	  (Kuhn,	  2004)	  There	  are	  five	  recognized	  subtypes	  of	  schizophrenia:	  paranoid,	  
disorganized,	  catatonic,	  undifferentiated,	  and	  residual.	  Schizophrenia	  symptoms	  are	  very	  hard	  to	  define	  
and	  many	  categories	  of	  symptoms	  are	  used	  in	  diagnosis	  and	  treatment.	  (Tsuang,	  2000)	  However,	  the	  
two	  main	  categories	  are	  positive	  and	  negative	  symptoms.	  Positive	  symptoms	  are	  forms	  of	  psychosis	  and	  
include	  delusions,	  auditory	  hallucinations,	  and	  thought	  disorder.	  Thought	  disorder	  may	  encompass	  
tangible	  symptoms	  such	  as,	  having	  trouble	  completing	  a	  sentence,	  thinking	  through	  an	  idea,	  answering	  a	  
question	  clearly,	  or	  carrying	  out	  routine	  tasks.	  An	  interestingly	  common	  and	  severe	  symptom	  is	  called	  
insertion	  or	  withdrawal	  of	  thought,	  which	  refers	  to	  the	  patient's	  misconception	  that	  someone	  or	  
something	  can	  put	  thoughts	  in	  the	  patient's	  head	  or	  take	  them	  out.	  (Tsuang,	  1997)	  Negative	  symptoms,	  
which	  are	  more	  common,	  include	  flat	  or	  blunted	  affect	  (the	  lack	  of	  emotion),	  alogia	  (poor	  speech	  
abilities),	  anhedonia	  (the	  inability	  to	  experience	  pleasure),	  and	  avolition,	  (Tsuang,	  1997).	  	  
Schizophrenics	  are	  likely	  to	  have	  comorbid	  conditions,	  including	  major	  depression	  and	  anxiety	  
disorders,	  (Sim,	  2006).	  Schizophrenia	  also	  increases	  the	  lifetime	  substance	  abuse	  prevalence	  from	  17%	  
in	  the	  general	  U.S.	  population	  (Sussman,	  2008)	  to	  around	  40%	  in	  the	  population	  of	  schizophrenics	  
(Friedman,	  2000).	  Schizophrenia	  leads	  to	  many	  social	  problems,	  including	  long-­‐term	  unemployment,	  
poverty	  and	  homelessness,	  and	  schizophrenics	  are	  often	  unable	  to	  function	  independently	  and	  may	  
become	  a	  burden	  to	  their	  families	  or	  require	  hospitalization.	  (Friedman,	  2000)	  There	  is	  a	  higher	  than	  
average	  suicide	  rate	  associated	  with	  schizophrenia	  which	  has	  been	  cited	  as	  high	  as	  10%,	  although	  recent	  
analysis	  of	  studies	  and	  statistics	  revises	  the	  estimate	  at	  4.9%,	  (Palmer,	  2005).	  In	  addition,	  many	  of	  the	  
antipsychotics	  have	  unhealthy	  side	  effects,	  such	  as	  weight	  gain	  and	  increased	  prevalence	  to	  diabetes.	  
This	  combined	  with	  the	  higher	  suicide	  rate	  in	  schizophrenics,	  has	  led	  to	  the	  average	  life	  expectancy	  of	  
people	  with	  the	  disorder	  being	  ten	  to	  12	  years	  less	  than	  those	  without	  schizophrenia.	  (Wahlbeck,	  2007)	  
Causes 
The	  cause	  of	  schizophrenia	  remains	  unknown	  and	  has	  been	  the	  subject	  of	  debate	  for	  centuries.	  
Studies	  suggest	  that	  genetics,	  early	  environment,	  neurobiology,	  psychological	  and	  social	  processes	  are	  
important	  contributory	  factors.	  Some	  recreational	  and	  prescription	  drugs,	  including	  cocaine	  and	  
amphetamines,	  appear	  to	  cause	  or	  worsen	  symptoms.	  (Friedman,	  2000)	  Current	  psychiatric	  research	  is	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focused	  on	  the	  role	  of	  neurobiology,	  but	  no	  single	  organic	  cause	  schizophrenia	  has	  been	  found.	  (Susser,	  
2002)	  
For	  much	  of	  the	  twentieth	  century,	  scientists	  thought	  that	  stressful	  or	  traumatic	  conditions	  (such	  as	  
abuse)	  in	  a	  person's	  life	  could	  cause	  mental	  disorders.	  (Friedman,	  2000)	  This	  theory	  is	  now	  less	  popular	  
with	  scientists,	  who	  generally	  agree	  that	  the	  disease	  is	  biological	  and	  not	  caused	  by	  life	  experience.	  For	  
example,	  research	  shows	  that	  the	  condition	  tends	  to	  run	  in	  families.	  A	  person	  with	  schizophrenic	  
relatives	  is	  ten	  times	  as	  likely	  to	  develop	  schizophrenia	  as	  someone	  who	  has	  no	  history	  of	  the	  disease	  in	  
the	  family.	  (Tsuang,	  1997)	  
There	  is	  evidence	  to	  support	  NRG1	  and	  DTNBP1	  as	  schizophrenia	  susceptibility	  loci,	  although	  further	  
research	  is	  required	  to	  understand	  how	  genetic	  variation	  at	  each	  locus	  confers	  susceptibility	  and	  
protection.	  (O'Donovan,	  2003)	  Also,	  some	  researchers	  have	  argued	  that	  schizophrenia	  is	  caused	  by	  a	  
virus	  that	  attacks	  the	  brain.	  However,	  the	  most	  widely	  accepted	  theory	  is	  that	  schizophrenia	  is	  caused	  
by	  an	  imbalance	  of	  neurotransmitters	  in	  the	  brain.	  (Patterson,	  2006)	  This	  influential	  theory,	  known	  as	  
the	  dopamine	  hypothesis	  of	  schizophrenia,	  proposed	  that	  excess	  activation	  of	  D2	  dopamine	  receptors	  
was	  the	  cause	  of	  the	  positive	  symptoms	  of	  schizophrenia.	  The	  hypothesis	  was	  originally	  based	  primarily	  
on	  the	  accidental	  finding	  that	  a	  drug	  group	  which	  blocks	  dopamine	  function,	  known	  as	  the	  
phenothiazines,	  could	  reduce	  psychotic	  symptoms	  and	  the	  fact	  that	  amphetamines,	  which	  trigger	  the	  
release	  of	  dopamine,	  may	  exacerbate	  the	  psychotic	  symptoms	  in	  schizophrenia.	  (Laruelle,	  1996)	  
Brain	  imaging	  technology,	  such	  as	  fMRI,	  CT,	  and	  PET,	  has	  shown	  that	  there	  are	  physical	  differences	  
in	  the	  brains	  of	  schizophrenics,	  which	  supports	  the	  idea	  that	  the	  cause	  of	  schizophrenia	  is	  biological.	  
Studies	  supporting	  the	  dopamine	  hypothesis	  have	  shown	  that	  the	  functional	  differences	  in	  brain	  activity	  
between	  normal	  and	  schizophrenic	  brains	  seem	  to	  most	  commonly	  occur	  in	  the	  frontal	  lobes	  (an	  area	  of	  
the	  brain	  which	  contains	  most	  of	  the	  dopamine-­‐sensitive	  neurons	  in	  the	  cerebral	  cortex),	  hippocampus	  
and	  temporal	  lobes.	  (Kircher,	  2006)	  Still,	  there	  is	  no	  consensus	  as	  to	  which,	  if	  any,	  of	  these	  theories	  is	  
correct.	  It	  could	  be	  very	  possible	  that	  the	  disease	  is	  caused	  by	  a	  combination	  of	  factors.	  
Diagnosis 
Since	  there	  is	  no	  specific	  cause	  of	  schizophrenia,	  it	  is	  diagnosed	  on	  the	  basis	  of	  symptom	  profiles.	  
Psychiatric	  assessment	  includes	  a	  psychiatric	  history	  and	  some	  form	  of	  mental	  status	  examination.	  
(American	  Psychiatric	  Association,	  2000)	  Exactly	  what	  schizophrenia	  is,	  and	  should	  be	  defined	  as,	  has	  
been	  the	  source	  of	  considerable	  disagreement	  among	  psychiatrists.	  Due	  to	  the	  many	  possible	  
combinations	  of	  symptoms,	  there	  is	  even	  debate	  about	  whether	  the	  diagnosis	  represents	  a	  single	  
disorder	  or	  a	  number	  of	  discrete	  syndromes.	  (Friedman,	  2000)	  This	  is	  why	  Eugen	  Bleuler	  actually	  termed	  
the	  disease	  the	  schizophrenias,	  when	  he	  coined	  the	  name,	  to	  emphasize	  the	  appearance	  of	  several	  
discrete	  syndromes,	  (Kuhn,	  2004).	  
There	  are	  currently	  no	  laboratory	  tests	  by	  which	  schizophrenia	  can	  be	  diagnosed.	  However,	  some	  
imaging	  techniques	  can	  be	  helpful	  in	  showing	  abnormal	  structures	  in	  the	  brain.	  For	  example,	  individuals	  
with	  schizophrenia,	  including	  those	  who	  have	  never	  been	  treated,	  typically	  have	  enlarged	  ventricles	  in	  
the	  brain,	  as	  demonstrated	  in	  over	  100	  studies	  to	  date.	  They	  have	  a	  reduced	  volume	  of	  gray	  matter	  (up	  
to	  25%	  in	  some	  areas)	  in	  the	  brain,	  especially	  in	  the	  temporal	  and	  frontal	  lobes.	  (Barrow,	  2008)	  Some	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studies	  have	  reported	  that	  about	  half	  of	  the	  chronic	  cases	  of	  schizophrenia	  were	  also	  shown	  to	  exhibit	  
hypofrontality	  in	  the	  brain	  at	  rest,	  a	  condition	  in	  which	  strong	  associations	  with	  the	  negative	  symptoms	  
of	  schizophrenia	  have	  been	  reported,	  (Sharafi,	  2005).	  For	  the	  most	  part,	  however,	  doctors	  must	  observe	  
a	  patient's	  behavior	  to	  decide	  if	  he	  or	  she	  is	  schizophrenic,	  and	  to	  rule	  out	  other	  physical	  and	  mental	  
disorders	  with	  similar	  symptoms,	  such	  as	  encephalitis,	  (American	  Psychiatric	  Association,	  2000).	  
Refractory	  Schizophrenia	  
Refractory,	  or	  treatment-­‐resistant,	  schizophrenia	  is	  defined	  in	  practice	  as	  the	  failure	  of	  symptoms	  to	  
respond	  satisfactorily	  to	  at	  least	  two	  different	  antipsychotics.	  However,	  the	  precise	  definition	  is	  still	  
controversial.	  (Meltzer,	  1997)	  Approximately	  30%	  (range	  10-­‐45%)	  of	  schizophrenic	  patients	  meet	  the	  
criteria	  for	  refractory	  schizophrenia,	  according	  to	  at	  least	  two	  reports,	  (Meltzer,	  1997	  and	  Bressan,	  
2007).	  Although	  some	  averages	  are	  slightly	  lower	  at	  25%,	  (Meltzer,	  1997).	  Of	  the	  remaining	  70%	  of	  
schizophrenic	  patients	  whose	  positive	  symptoms	  respond	  adequately	  to	  antipsychotic	  treatment,	  many	  
may	  still	  have	  clinically	  significant	  negative	  symptoms	  and	  cognitive	  function,	  and	  poor	  social	  and	  work	  
function.	  This	  can	  mean	  that	  although	  these	  patients	  no	  longer	  experience	  severe	  positive	  symptoms	  
they	  still	  suffer	  poor	  quality	  of	  life	  relative	  to	  the	  normal	  population	  and/or	  continue	  to	  constitute	  a	  
significant	  burden	  to	  family	  and	  society.	  
Since	  refractory	  schizophrenics	  exhibit	  severe	  symptoms	  unique	  to	  this	  condition	  which	  lead	  to	  
more	  frequent	  and	  longer	  duration	  hospitalizations,	  their	  treatment	  is	  generally	  much	  more	  expensive	  
than	  that	  of	  neuroleptic-­‐responsive	  patients.	  They	  usually	  have	  poorer	  premorbid	  function,	  an	  earlier	  
age	  at	  onset	  of	  positive	  symptoms,	  and	  more	  sever	  cognitive	  dysfunction.	  Even	  magnetic	  resonance	  
imaging	  scans	  show	  that	  these	  patients	  have	  features	  unique	  from	  other	  schizophrenics,	  such	  as	  various	  
quantitative	  types	  of	  cortical	  or	  ventricular	  abnormalities.	  Commonly	  used	  techniques	  for	  inducing	  
responsiveness,	  such	  as	  increased	  dosages	  of	  neuroleptic	  drugs,	  switching	  to	  other	  types	  of	  
neuroleptics,	  or	  adding	  adjunctive	  agents	  such	  as	  antidepressants	  or	  anticonvulsants	  does	  not	  work	  in	  
refractory	  schizophrenics.	  (Meltzer,	  1997)	  It	  is	  clear	  that	  refractory	  schizophrenia	  represents	  a	  challenge	  
to	  clinicians	  and	  that	  it	  is	  often	  under	  diagnosed	  and	  undertreated.	  (Bressan,	  2007)	  	  
Treatment	  
The	  primary	  form	  of	  treatment	  for	  schizophrenia	  is	  medication,	  and	  drugs	  are	  now	  available	  to	  
control	  many	  of	  the	  symptoms	  of	  the	  disorder.	  Most	  of	  these	  medications	  alleviate	  the	  symptoms,	  but	  
never	  ‘cure’	  the	  disease.	  (Barrow,	  2008)	  Between	  60	  to	  70	  percent	  of	  patients	  with	  schizophrenia	  
respond	  to	  drug	  treatment.	  The	  most	  successful	  medications	  used	  in	  the	  treatment	  of	  schizophrenia	  are	  
neurotransmitter	  antagonists.	  Schizophrenia	  is	  a	  complicated	  disorder	  with	  many	  different	  forms	  of	  
manifestation.	  In	  accord	  with	  logic,	  patients	  do	  not	  only	  manifest	  different	  forms	  of	  schizophrenia	  but	  
they	  also	  respond	  differently	  to	  different	  treatments.	  (Patterson,	  2006)	  This	  is	  in	  part	  the	  reason	  for	  
great	  value	  in	  having	  as	  many	  different	  effective	  medications	  as	  possible.	  Although	  most	  researchers	  
believe	  that	  schizophrenia	  is	  a	  biological	  problem	  rather	  than	  a	  problem	  caused	  by	  early	  upbringing	  or	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life	  events,	  psychotherapy,	  including	  counseling	  and	  behavior	  therapy,	  is	  often	  part	  of	  the	  treatment	  
plan	  for	  a	  schizophrenic.	  (Friedman,	  2000)	  
Drugs	  for	  Treating	  Schizophrenia	  
There	  are	  two	  classes	  of	  antipsychotics:	  typical,	  or	  first	  generation,	  and	  atypical,	  or	  second	  
generation,	  antipsychotics.	  Typical	  antipsychotics	  were	  first	  introduced	  in	  the	  1950s	  and	  are	  divided	  into	  
high-­‐potency,	  fluphenazine	  and	  haloperidol,	  and	  low-­‐potency,	  chlorpromazine,	  drugs.	  These	  drugs	  are	  
known	  to	  have	  many	  symptoms,	  the	  most	  notable	  of	  which	  are	  the	  extrapyramidal	  side	  effects	  (EPS).	  
(Wang,	  2005)	  EPS	  is	  characterized	  by	  tremor,	  slurred	  speech,	  akithisia	  (a	  movement	  disorder	  
characterized	  by	  inner	  restlessness	  and	  the	  inability	  to	  sit	  or	  stand	  still),	  dystonia	  (a	  neurological	  
movement	  disorder	  characterized	  by	  involuntary	  muscle	  contractions),	  bradyphrenia	  (a	  slowing	  of	  
thought	  processes),	  and	  bradykinesia	  (a	  slowing	  of	  movement	  and	  muscular	  rigidity).	  The	  side	  effects	  
resemble	  the	  signs	  of	  Parkinson's	  disease,	  which	  are	  associated	  with	  degeneration	  of	  the	  dopamine	  
nerve	  tracks	  located	  in	  the	  extrapyramidal	  region	  of	  the	  central	  nervous	  system.	  (Weiden,	  2007)	  In	  
addition,	  with	  typical	  antipsychotics	  there	  is	  a	  significant	  risk	  of	  the	  serious	  condition	  tardive	  dyskinesia,	  
which	  develops	  in	  approximately	  30	  percent	  of	  the	  patients,	  (Llorca,	  2002).	  Another	  serious	  side	  effect	  
that	  is	  most	  common	  amongst	  the	  typical	  antipsychotics	  is	  neuroleptic	  malignant	  syndrome	  (NMS),	  a	  
life-­‐threatening	  neurological	  disorder.	  (Ananth,	  2004)	  Long-­‐term	  treatment	  of	  schizophrenia	  with	  typical	  
antipsychotics	  has	  limitations,	  since	  it	  results	  in	  25	  to	  30	  percent	  of	  the	  patients	  showing	  treatment-­‐
resistance.	  (Wahlbeck,	  2007)	  
Atypical	  antipsychotics,	  such	  as	  clozapine,	  are	  actually	  a	  group	  of	  unrelated	  drugs	  that	  are	  grouped	  
together	  simply	  because	  they	  work	  differently	  from	  typical	  antipsychotics.	  Both	  typical	  and	  atypical	  
antipsychotics	  block	  dopamine	  D2	  receptors	  and	  signal	  transmissions	  by	  dopamine.	  This	  mechanism	  of	  
symptom	  relief	  is	  in	  accord	  with	  the	  dopamine	  hypothesis	  that	  schizophrenia	  is	  associated	  with	  
increased	  activity	  in	  dopaminergic	  neurons.	  (Sharafi,	  2005)	  However,	  atypicals	  are	  different	  from	  typical	  
antipsychotics	  in	  their	  mechanism	  of	  action	  since	  most	  act	  on	  serotonin	  receptors	  as	  well	  as	  dopamine	  
receptors,	  (Seeman,	  2002).	  The	  first	  atypical	  anti-­‐psychotic	  medication,	  clozapine,	  was	  introduced	  in	  the	  
1970s.	  Next,	  olanzapine,	  risperidone	  and	  quetiapine	  were	  introduced	  in	  the	  1990s,	  and	  ziprasidone	  and	  
aripiprazole	  followed	  in	  the	  early	  2000s.	  Paliperidone	  is	  the	  latest	  atypical	  to	  be	  approved	  by	  the	  FDA	  in	  
2006.	  (Weiden,	  2007)	  The	  most	  strikingly	  different	  clinical	  effect	  of	  atypical	  drugs	  is	  their	  decreased	  
propensity	  to	  cause	  EPS,	  (Farah,	  2005).	  The	  definition	  of	  an	  atypical	  antipsychotic	  was	  based	  upon	  the	  
absence	  of	  EPS	  found	  in	  clozapine,	  the	  first	  atypical	  antipsychotic.	  The	  atypical	  drugs	  that	  followed	  
clozapine	  have	  now	  been	  shown	  to	  still	  induce	  EPS,	  although	  to	  a	  lesser	  degree	  than	  typical	  
antipsychotics.	  Since	  all	  of	  the	  post-­‐clozapine	  atypical	  antipsychotics	  still	  affect	  the	  dopamine	  D2	  
receptor,	  the	  continued	  presence	  of	  EPS	  is	  consistent	  with	  its	  hypothesized	  mechanism.	  (Weiden,	  2007)	  
But	  fewer	  patients	  will	  get	  EPS	  at	  therapeutic	  doses	  of	  one	  of	  the	  atypical	  antipsychotics	  than	  the	  typical	  
antipsychotics,	  and	  when	  EPS	  do	  occur,	  they	  tend	  to	  be	  less	  severe.	  Therefore,	  most	  researchers	  agree	  
that	  atypical	  antipsychotics,	  in	  general,	  have	  lower	  EPS	  liabilities.	  	  
Clozapine,	  an	  atypical	  antipsychotic,	  is	  more	  effective	  in	  treating	  schizophrenia	  than	  typical	  
antipsychotics	  and	  may	  help	  to	  reduce	  relapses,	  suicide	  and	  necessary	  hospitalization,	  as	  demonstrated	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in	  a	  2005	  comparison	  study.	  The	  study	  combined	  neuropsychological	  evaluation	  and	  positive	  and	  
negative	  syndrome	  scale	  of	  schizophrenia	  (PANSS)	  scores,	  with	  single	  photon	  emission	  computed	  
tomography	  (SPECT)	  to	  detect	  differences	  in	  the	  effectiveness	  of	  clozapine	  and	  typical	  antipsychotics.	  
After	  treatment,	  different	  brain	  focal	  abnormalities	  in	  the	  two	  groups	  were	  observed	  and	  differences	  in	  
PANSS	  scores	  were	  significant	  in	  both	  groups,	  with	  superior	  scores	  resulting	  from	  treatment	  with	  
clozapine.	  Results	  were	  supported	  by	  SPECT,	  which	  showed	  a	  greater	  improvement	  in	  the	  clozapine	  
group.	  Both	  positive	  and	  negative	  symptoms	  were	  improved	  with	  clozapine	  as	  well.	  Before	  treatment,	  
hypofrontality,	  which	  is	  strongly	  associated	  with	  negative	  symptoms,	  occurred	  in	  85%	  of	  the	  patient’s	  
brains	  and	  most	  cases	  of	  hypofrontality	  were	  cleared	  after	  treatment	  with	  clozapine.	  An	  interesting	  
finding	  in	  the	  study	  may	  explain	  why	  clozapine	  is	  more	  effective,	  especially	  with	  refractory	  
schizophrenia;	  there	  was	  a	  significantly	  increased	  rCBF	  observed	  in	  the	  thalamus	  that	  was	  more	  
prominent	  in	  clozapine-­‐treated	  patients,	  which	  could	  be	  due	  to	  clozapine’s	  greater	  effect	  on	  the	  
thalamus	  by	  dopaminergic	  receptors.	  (Sharafi,	  2005)	  
Although	  there	  is	  some	  evidence	  that	  non-­‐clozapine	  atypical	  antipsychotics	  are	  more	  advantageous	  
than	  typical	  drugs,	  clozapine	  is	  superior	  to	  these	  other	  atypical	  drugs	  as	  well.	  Clozapine	  is	  known	  to	  have	  
the	  fewest	  EPS	  of	  all	  antipsychotics,	  including	  the	  other	  atypicals,	  (Weiden,	  2007).	  According	  to	  a	  
systematic	  review	  in	  2003	  comparing	  the	  EPS	  in	  atypical	  antipsychotics	  and	  low-­‐potency	  typical	  
antipsychotics,	  only	  clozapine	  was	  associated	  with	  significantly	  fewer	  EPS	  (RD=–0.15,	  95%	  CI	  −0.26	  to	  
−0.4,	  p=0.008)	  and	  higher	  efficacy	  than	  low-­‐potency	  typical	  drugs,	  (Leucht,	  2003).	  According	  to	  a	  trial	  
conducted	  by	  Jones	  in	  2006,	  there	  is	  no	  disadvantage	  across	  one	  year	  in	  terms	  of	  quality	  of	  life,	  
symptoms,	  or	  associated	  costs	  of	  care	  in	  using	  typical	  versus	  non-­‐clozapine	  atypical	  antipsychotics.	  It	  is	  
important	  to	  note	  that	  the	  superiority	  of	  clozapine	  in	  this	  trial	  was	  neither	  the	  result	  of	  inadequate	  
power	  nor	  patterns	  of	  drug	  discontinuation.	  (Jones,	  2006)	  In	  addition,	  clozapine	  is	  the	  only	  drug	  that	  is	  
consistently	  effective	  in	  the	  population	  of	  treatment-­‐refractory	  schizophrenics.	  In	  2000,	  David	  Taylor	  
developed	  a	  refractoriness	  rating	  based	  on	  previous	  work	  evaluating	  other	  atypicals	  as	  treatments	  for	  
refractory	  schizophrenia.	  The	  goal	  was	  to	  evaluate	  the	  current	  evidence	  of	  effectiveness	  of	  other	  
atypical	  antipsychotics	  in	  comparison	  to	  clozapine.	  He	  did	  this	  by	  assessing	  all	  trials	  of	  atypical	  drugs	  in	  
schizophrenia	  unresponsive	  to	  at	  least	  one	  drug	  with	  the	  refractoriness	  rating	  he	  developed.	  His	  analysis	  
determined	  that	  clozapine	  should	  remain	  the	  drug	  of	  choice	  to	  treat	  refractory	  schizophrenia,	  since	  
there	  was	  no	  evidence	  to	  support	  the	  use	  of	  any	  of	  the	  other	  atypical	  drugs.	  Even	  when	  using	  stringently	  
defined	  refractoriness	  ratings,	  clozapine	  was	  consistently	  shown	  to	  be	  more	  effective.	  (Taylor,	  2000)	  
Unfortunately,	  clozapine	  has	  several	  adverse	  effects	  that	  do	  extend	  beyond	  agranulocytosis,	  which	  
is	  the	  adverse	  effect	  focused	  on	  in	  this	  study.	  Clozapine	  must	  carry	  five	  black	  box	  warnings	  for	  
agranulocytosis,	  seizures,	  myocarditis,	  other	  adverse	  cardiovascular	  and	  respiratory	  effects,	  and	  
increased	  mortality	  in	  elderly	  patients	  with	  dementia-­‐related	  psychosis.	  Myocarditis	  usually	  develops	  
after	  approximately	  one	  month	  of	  starting	  the	  drug	  and	  it	  presents	  with	  obvious	  signs	  of	  illness.	  
However,	  cardiomyopathy	  is	  also	  potentially	  life	  threatening	  and	  could	  arise	  suddenly	  or	  go	  undetected.	  
Consequently,	  a	  regular	  six-­‐monthly	  echocardiogram	  was	  recently	  recommended	  when	  treating	  a	  
patient	  with	  clozapine.	  (Haas,	  2007)	  Clozapine	  is	  also	  known	  to	  cause	  gastrointestinal	  hypomotility,	  
(Palmer,	  2008)	  and	  deficiency	  of	  selenium,	  (Vaddadi,	  2003).	  Available	  data	  indicates	  that	  clozapine	  and	  
olanzapine	  are	  associated	  with	  the	  greatest	  effects	  on	  weight	  gain	  and	  decreased	  insulin	  sensitivity,	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followed	  by	  risperidone	  and	  quetiapine.	  Therefore,	  clozapine	  (along	  with	  other	  atypical	  antipsychotics)	  
results	  in	  increased	  susceptibility	  to	  weight	  gain	  and	  obesity	  related	  illnesses,	  particularly	  diabetes,	  and	  
may	  increase	  this	  susceptibility	  more	  than	  most	  typical	  drugs.	  (American	  Diabetes	  Association,	  2004)	  
However,	  the	  primary	  risk	  with	  clozapine	  and	  the	  primary	  factor	  relegating	  clozapine	  to	  its	  status	  as	  a	  
last	  resort	  drug	  remains	  agranulocytosis.	  Eliminating	  this	  lethal	  side	  effect	  would	  make	  clozapine	  much	  
more	  relatively	  safe	  in	  comparison	  to	  the	  other	  antipsychotics.	  
Materials	  and	  Methods	  
Developing	  the	  assay	  for	  clozapine-­‐induced	  yeast	  cell	  growth	  inhibition	  
In	  order	  to	  determine	  if	  clozapine	  does	  indeed	  cause	  inhibition	  of	  growth	  in	  yeast	  cells,	  many	  liquid	  
yeast	  cultures	  of	  the	  S.	  cerevisiae	  Y101	  yeast	  strain	  were	  experimented	  with	  under	  different	  reaction	  
mixture	  conditions.	  Different	  amounts	  of	  yeast,	  clozapine,	  HRP,	  H202	  and	  DMSO	  were	  combined	  and	  the	  
cellular	  density	  was	  determined	  after	  zero,	  eight	  and	  12	  hours	  of	  culture.	  Educated	  trial	  and	  error	  was	  
necessary	  to	  determine	  if	  some	  specific	  combination	  of	  different	  concentrations	  of	  each	  variable	  would	  
result	  in	  an	  assay	  that	  does	  show	  dosage	  dependent	  inhibition	  of	  yeast	  cell	  growth	  by	  clozapine.	  
Eventually,	  this	  goal	  was	  reached	  and	  a	  total	  of	  11	  trials	  with	  Y101,	  clozapine	  and	  H202	  resulted	  in	  
dosage	  dependent	  inhibition	  of	  cell	  growth.	  Each	  96-­‐well	  plate	  trial	  contained	  duplicates	  of	  each	  
reaction	  mixture,	  meaning	  that	  a	  total	  of	  22	  sets	  of	  reaction	  mixtures	  at	  different	  concentrations	  of	  
clozapine	  and	  H202	  showed	  that	  clozapine	  does	  negatively	  affect	  cell	  growth.	  
The	  inspiration	  for	  this	  project	  came	  from	  Dr.	  Abraham	  Kovoor’s	  lab	  (University	  of	  Rhode	  Island).	  
They	  worked	  to	  show	  that	  yeast	  cell	  growth	  is	  negatively	  affected	  by	  clozapine,	  in	  the	  presence	  of	  H2O2,	  
and	  could	  therefore	  possibly	  serve	  as	  a	  model	  for	  investigating	  clozapine-­‐induced	  white	  blood	  cell	  
death.	  They	  were	  able	  to	  produce	  a	  trial	  that	  resulted	  in	  dosage	  dependent	  yeast	  cell	  growth	  inhibition	  
by	  clozapine,	  but	  were	  not	  able	  to	  repeat	  the	  results,	  see	  Figure	  2.	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Figure	  2.	  Clozapine-­‐induced	  yeast	  cell	  growth	  inhibition	  in	  the	  presence	  of	  H2O2	  -­‐	  Results	  of	  Dr.	  
Abraham	  Kovoor’s	  lab	  from	  the	  24th	  of	  January,	  2008	  
	  
We	  first	  began	  by	  culturing	  the	  Y101	  yeast	  strain	  in	  different	  media	  to	  determine	  which	  would	  
produce	  the	  optimal	  yeast	  growth.	  YNB+	  media	  containing	  the	  necessary	  amino	  acids	  (His,	  Leu,	  Lys,	  and	  
Ura)	  did	  not	  allow	  for	  strong	  enough	  yeast	  growth.	  Spectrophotometer	  plate	  readings	  of	  the	  culture	  
absorbance	  at	  600	  nm	  did	  not	  show	  yeast	  growth	  greater	  than	  0.1	  and	  there	  was	  no	  visible	  turbidity.	  
However,	  synthetic	  complete	  (SC)	  media	  did	  result	  in	  visible	  yeast	  culture	  growth	  in	  96-­‐well	  plates	  with	  
100	  mL	  of	  SC	  media	  in	  each	  well.	  YPD	  media	  was	  used	  to	  grow	  starting	  liquid	  cultures	  of	  the	  Y101	  yeast	  
strain	  from	  a	  frozen	  stock	  plate.	  
Once	  it	  was	  established	  that	  Y101	  would	  grow	  properly	  in	  YPD	  and	  SC	  media,	  the	  correct	  amount	  of	  
yeast	  for	  each	  reaction	  mixture	  had	  to	  be	  established.	  As	  variables	  were	  added	  to	  the	  reaction	  mixture	  
the	  ideal	  yeast	  concentration	  was	  continuously	  changed	  or	  adjusted	  to	  produce	  optimal	  yeast	  growth	  in	  
order	  to	  assay	  the	  affect	  of	  clozapine.	  Many	  aspects	  of	  the	  protocol	  were	  changed	  to	  result	  in	  different	  
yeast	  concentrations	  throughout	  the	  trial	  and	  error	  experimentation	  with	  different	  concentrations	  of	  
the	  five	  variables	  (yeast,	  clozapine,	  DMSO,	  H202,	  and	  HRP):	  
• The	  time	  for	  the	  YPD	  liquid	  culture	  to	  grow	  was	  adjusted	  from	  one	  to	  two	  days.	  
• The	  amount	  of	  YPD	  liquid	  media	  in	  the	  original	  liquid	  yeast	  culture	  varied	  from	  1.5	  mL	  to	  5	  mL.	  
• The	  amount	  of	  a	  5	  mL	  YPD	  overnight	  culture	  that	  was	  used	  varied	  from	  an	  entire	  5	  mL	  overnight	  	  
culture	  to	  seven	  decreasing	  yeast	  concentrations	  produced	  by	  a	  1:10	  dilution	  series	  of	  a	  5	  mL	  
overnight	  culture.	  
• At	  one	  point,	  two	  5	  mL	  YPD	  liquid	  cultures	  were	  spun	  down	  and	  washed	  and	  the	  resulting	  yeast	  	  
cells	  were	  combined	  and	  brought	  back	  up	  in	  1	  mL	  of	  SC	  media.	  This	  liquid	  yeast	  culture	  was	  then	  
used	  to	  produce	  seven	  decreasing	  concentrations	  of	  yeast	  in	  a	  1:10	  dilution	  series.	  	  
• Not	  only	  was	  the	  concentration	  of	  the	  liquid	  yeast	  culture	  added	  to	  the	  reaction	  mixture	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manipulated,	  but	  the	  amount	  of	  the	  culture	  added	  also	  varied	  from	  10	  µL	  to	  40	  µL	  of	  yeast	  
culture.	  
The	  concentrations	  of	  DMSO	  and	  H202	  were	  also	  experimented	  with	  at	  length.	  Before	  clozapine	  was	  
added	  to	  the	  reaction	  mixtures,	  it	  was	  important	  to	  determine	  the	  concentrations	  of	  DMSO	  and	  H2O2	  
that	  could	  be	  tolerated	  by	  different	  concentrations	  of	  yeast.	  DMSO	  is	  the	  necessary	  solvent	  for	  clozapine	  
and	  would	  therefore	  have	  to	  be	  present	  in	  the	  reaction	  mixtures.	  H202	  was	  hypothesized	  to	  have	  a	  role	  
in	  the	  mechanism	  by	  which	  clozapine	  induces	  cell	  death	  in	  white	  blood	  cells,	  therefore	  some	  of	  the	  
reaction	  mixtures	  would	  have	  to	  contain	  H202	  to	  determine	  whether	  or	  not	  H202	  is	  also	  necessary	  for	  
clozapine-­‐induced	  yeast	  cell	  death	  and/or	  yeast	  cellular	  growth	  inhibition.	  Both	  DMSO	  and	  H202	  are	  toxic	  
to	  yeast	  cells	  in	  their	  own	  right.	  Therefore,	  it	  was	  necessary	  to	  determine	  the	  proper	  concentration	  of	  
DMSO,	  H202,	  and	  yeast	  cells	  that	  would	  still	  result	  in	  appropriate	  yeast	  cell	  growth.	  Different	  
combinations	  of	  decreasing	  yeast,	  DMSO,	  and	  H202	  concentrations	  were	  tested	  to	  find	  the	  appropriate	  
concentrations	  that	  would	  not	  result	  in	  overly	  strong	  cell	  growth	  (since	  the	  strongly	  growing	  cultures	  
may	  simply	  grow	  too	  strong	  to	  show	  the	  affects	  of	  clozapine),	  but	  that	  would	  still	  result	  in	  cell	  growth	  
sufficient	  enough	  to	  test	  the	  effect	  of	  clozapine	  on	  its	  growth.	  High	  concentrations	  of	  DMSO	  and	  H202	  
resulted	  in	  no	  cell	  growth	  even	  at	  high	  concentrations	  of	  starting	  yeast	  culture,	  indicating	  the	  
importance	  of	  accounting	  for	  and	  controlling	  the	  toxic	  effects	  of	  DMSO	  and	  H202.	  The	  DMSO	  amounts	  
varied	  from	  2.5	  µL	  to	  20	  µL	  and	  H202	  concentrations	  varied	  from	  1%	  to	  1	  X	  10-­‐10%.	  Once	  yeast	  was	  
growing	  in	  the	  presence	  of	  DMSO	  and	  H202,	  clozapine	  could	  be	  added	  and	  cellular	  growth	  inhibition	  
could	  be	  safely	  concluded	  to	  be	  resulting	  from	  clozapine	  and	  not	  the	  other	  toxic	  compounds	  alone	  
(DMSO	  and	  H202).	  
When	  clozapine	  was	  added	  at	  varied	  concentrations	  of	  5	  µM	  to	  20	  µM,	  the	  variables	  of	  yeast	  
concentration	  and	  H202	  again	  had	  to	  be	  manipulated	  to	  result	  in	  yeast	  growth.	  The	  proper	  amount	  of	  
DMSO	  to	  be	  tolerated	  by	  yeast	  cells	  had	  been	  determined	  to	  be	  5	  µL	  of	  DMSO.	  Therefore,	  the	  different	  
clozapine	  concentrations	  were	  diluted	  with	  water	  so	  that	  all	  three	  concentrations	  resulted	  in	  a	  solution	  
containing	  only	  5	  µL	  of	  DMSO.	  Yeast	  concentration	  was	  varied	  until	  yeast	  was	  growing	  properly	  in	  the	  
control	  wells	  (‘no	  clozapine’	  and	  ‘no	  clozapine	  or	  H202’)	  and	  growing	  to	  some	  extent	  in	  the	  reaction	  
mixtures	  containing	  clozapine.	  Once	  it	  was	  established	  that	  20	  µL	  of	  a	  2	  mL	  two-­‐day	  culture	  of	  YDP	  
would	  result	  in	  the	  proper	  yeast	  concentration,	  this	  exact	  amount	  of	  yeast	  was	  added	  to	  each	  well	  in	  the	  
96-­‐well	  plates	  thereafter,	  and	  no	  further	  manipulation	  of	  yeast	  concentration	  was	  necessary.	  
Next,	  we	  experimented	  to	  determine	  what	  concentrations	  of	  H2O2	  would	  still	  allow	  for	  yeast	  cell	  
growth	  but	  might	  also	  possibly	  allow	  for	  dosage	  dependent	  clozapine	  yeast	  cell	  growth	  inhibition.	  The	  
concentrations	  of	  H202	  and	  clozapine	  were	  still	  manipulated	  and	  many	  96-­‐well	  plates	  were	  created	  with	  
different	  combinations	  of	  five	  decreasing	  concentrations	  of	  H202	  and	  the	  increasing	  dosages	  of	  0	  µM,	  5	  
µM,	  10	  µM	  and	  20	  µM	  clozapine.	  Also	  present	  in	  these	  experimental	  plates	  was	  the	  fifth	  variable:	  HRP.	  
Up	  until	  this	  point,	  HRP	  had	  only	  been	  used	  in	  some	  of	  the	  trials	  to	  determine	  its	  effect,	  which	  was	  
decreased	  cellular	  growth	  inhibition.	  However,	  in	  this	  phase	  of	  the	  project,	  where	  we	  were	  attempting	  
to	  show	  dosage	  dependent	  clozapine-­‐induced	  yeast	  cell	  growth	  inhibition	  by	  testing	  the	  different	  
combinations	  of	  clozapine	  and	  H202	  concentrations,	  these	  combinations	  were	  tested	  both	  with	  and	  
without	  2U	  HRP.	  Figure	  3	  represents	  an	  example	  of	  the	  experimental	  set-­‐up	  in	  the	  plates	  used	  to	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determine	  the	  proper	  H202	  concentration	  that	  resulted	  in	  dosage	  dependent	  clozapine-­‐induced	  cell	  
growth	  inhibition	  of	  the	  Y101	  yeast	  cultures,	  of	  the	  predetermined	  concentration.	  




Clozapine	  inhibits	  growth	  of	  yeast	  in	  a	  dose	  dependent	  manner	  	  
The	  conditions	  to	  study	  the	  effects	  of	  clozapine	  were	  optimized	  using	  a	  growth	  inhibition	  assay,	  
performed	  in	  96-­‐well	  plates.	  Different	  combinations	  of	  varying	  concentrations	  of	  the	  four	  variables	  
involved	  in	  the	  reaction	  (clozapine,	  DMSO,	  H2O2,	  and	  HRP)	  were	  used,	  and	  three	  different	  
concentrations	  of	  yeast	  were	  tested.	  The	  assay	  was	  performed	  in	  100	  µL	  synthetic	  complete	  (SC)	  media	  
to	  which	  20	  µL	  of	  two-­‐day	  liquid	  yeast	  culture	  grown	  in	  1.5	  mL	  of	  YPD	  media	  was	  added.	  Clozapine,	  
solvated	  in	  5	  µL	  of	  DMSO,	  was	  used	  in	  the	  assay	  at	  the	  different	  concentrations	  of	  0	  µM,	  5	  µM,	  10	  µM	  
and	  20	  µM.	  Also,	  used	  in	  a	  successful	  assay	  was	  1%	  H2O2.	  
11	  trials	  resulted	  in	  culture	  absorbencies	  at	  600	  nm	  (A600)	  that	  indicated	  dose	  dependent	  clozapine-­‐
induced	  yeast	  cell	  growth	  inhibition	  in	  the	  presence	  of	  1%	  H2O2.	  Figure	  4	  is	  a	  representative	  trial	  with	  
the	  duplicate	  well	  data	  averaged.	  Data	  presented	  in	  Figure	  4	  indicates	  a	  negative	  correlation	  between	  
the	  concentration	  of	  clozapine	  and	  A600,	  suggesting	  that	  clozapine	  was	  inhibiting	  the	  growth	  of	  yeast	  
cells.	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Figure	  4.	  Represents	  the	  growth	  of	  yeast	  cells	  in	  the	  presence	  of	  increasing	  concentrations	  of	  
clozapine;	  one	  representative	  trail	  with	  duplicates	  averaged	  
	  
The	  data	  in	  Figure	  4	  shows	  that	  clozapine	  inhibits	  the	  growth	  of	  yeast	  at	  a	  concentration	  as	  low	  as	  5	  
µM,	  and	  this	  effect	  is	  exaggerated	  after	  12	  hours.	  	  Furthermore,	  the	  growth	  inhibition	  phenotype	  is	  dose	  
dependent.	  There	  is	  a	  striking	  decrease	  in	  A600	  reading	  between	  0	  µM	  clozapine	  and	  5	  µM	  clozapine	  
than	  between	  5	  µM	  clozapine	  and	  10	  µM	  clozapine.	  A600	  was	  also	  measured	  at	  20	  µM	  clozapine,	  but	  
there	  was	  no	  significant	  difference	  in	  growth	  inhibition	  between	  10	  µM	  clozapine	  and	  20	  µM	  clozapine	  
(data	  not	  shown).	  	  	  
The	  estimated	  minimum	  inhibitory	  concentration	  of	  clozapine	  for	  S.	  
cerevisiae	  is	  between	  5	  µM	  and	  10	  µM	  
The	  minimum	  inhibitory	  concentration	  (MIC50)	  is	  defined	  as	  the	  concentration	  of	  clozapine	  that	  
inhibits	  growth	  of	  50%	  of	  the	  yeast	  cells.	  	  From	  this	  study	  we	  can	  estimate	  that	  the	  MIC50	  for	  clozapine	  is	  
between	  5	  µM	  and	  10	  µM.	  To	  determine	  an	  exact	  MIC50	  we	  need	  to	  test	  more	  concentrations	  of	  
clozapine	  between	  5	  µM	  and	  10	  µM.	  	  For	  the	  purpose	  of	  this	  study	  we	  noted	  that	  yeast	  cell	  growth	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inhibitory	  concentration	  was	  estimated	  from	  the	  culture	  absorbance	  readings	  at	  600	  nm	  taken	  after	  12	  
hours	  of	  culture.	  Three	  96-­‐well	  plate	  trials	  were	  chosen	  to	  estimate	  the	  MIC50,	  because	  they	  showed	  the	  
clozapine-­‐induced	  cell	  growth	  inhibition	  phenotype	  most	  clearly.	  Since	  each	  plate	  contained	  duplicates,	  
this	  resulted	  in	  six	  culture	  absorbencies	  at	  each	  concentration	  of	  clozapine.	  Figure	  5	  represents	  a	  
simplified	  version	  of	  the	  graph	  used	  to	  determine	  the	  MIC50	  of	  yeast	  cells,	  with	  the	  average	  of	  the	  six	  
absorbencies	  at	  each	  clozapine	  concentration	  shown.	  The	  average	  culture	  absorbance	  for	  the	  six	  
reproducibly	  repeated	  trial	  absorbencies	  at	  600	  nm	  and	  after	  zero	  hours	  of	  culture	  was	  determined	  to	  
be	  0.377.	  When	  this	  was	  divided	  in	  half	  it	  resulted	  in	  0.189,	  which	  represents	  a	  cell	  culture	  at	  half	  the	  
average	  starting	  density.	  This	  absorbency	  of	  0.189	  intersected	  the	  curves	  representing	  the	  different	  
trials	  between	  the	  culture	  absorbencies	  for	  5	  µM	  clozapine	  and	  10	  µM	  clozapine,	  indicating	  that	  the	  
MIC50	  is	  some	  concentration	  between	  5	  µM	  and	  10	  µM	  clozapine.	  Figure	  5	  shows	  the	  average	  cell	  
density	  at	  each	  concentration	  of	  clozapine	  and	  the	  standard	  deviation	  of	  the	  averages.	  	  This	  graph	  also	  
shows	  that	  the	  MIC50	  of	  yeast	  cells	  for	  clozapine	  falls	  between	  5	  µM	  and	  10	  µM	  clozapine.	  	  
Figure	  5.	  Represents	  the	  average	  culture	  absorbance	  after	  12	  hours	  of	  incubation	  in	  the	  presence	  of	  
increasing	  concentrations	  of	  clozapine;	  average	  of	  three	  reproducibly	  repeated	  trials	  
	  
Discussion	  
The	  major	  contribution	  of	  this	  project	  was	  to	  establish	  that	  clozapine	  causes	  yeast	  cell	  growth	  
inhibition	  of	  S.	  cerevisiae,	  and	  consequently	  that	  S.	  cerevisiae	  may	  be	  able	  to	  serve	  as	  a	  model	  for	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cell	  growth	  inhibition,	  this	  assay	  can	  be	  used	  to	  screen	  the	  S.	  cerevisiae	  deletion	  library	  to	  identify	  genes	  
and	  pathways	  involved	  in	  clozapine’s	  mechanism	  of	  agranulocytosis.	  Clozapine	  causes	  a	  decrease	  in	  
WBC	  count	  by	  actually	  killing	  white	  blood	  cells	  and	  not	  by	  inhibiting	  their	  growth.	  It	  would	  be	  significant	  
to	  establish	  that	  clozapine	  also	  kills	  yeast	  cells,	  as	  it	  does	  white	  blood	  cells,	  and	  that	  the	  decreased	  
culture	  absorbance	  is	  not	  simply	  due	  to	  yeast	  cell	  growth	  inhibition.	  Yeast	  cell	  death	  can	  be	  easily	  
assayed	  using	  simple	  dyes	  that	  test	  cell	  viability.	  
Furthermore,	  performing	  this	  growth	  inhibition	  assay	  with	  other	  atypical	  antipsychotics,	  such	  as	  
olanzapine,	  would	  aid	  in	  further	  establishing	  whether	  or	  not	  the	  interaction	  between	  yeast	  and	  
clozapine	  can	  serve	  as	  a	  model	  for	  the	  interaction	  between	  yeast	  and	  white	  blood	  cells.	  If	  other	  atypical	  
antipsychotics,	  which	  do	  not	  induce	  agranulocytosis,	  do	  cause	  dosage	  dependent	  atypical	  drug-­‐induced	  
yeast	  cell	  growth	  inhibition	  then	  this	  would	  mean	  that	  the	  yeast	  cell	  growth	  inhibition	  caused	  by	  
clozapine	  might	  be	  due	  to	  a	  mechanism	  other	  than	  the	  mechanism	  that	  causes	  WBC	  death.	  Also,	  
removing	  the	  yeast	  cell	  wall	  before	  performing	  the	  same	  assay	  we	  developed	  would	  make	  the	  model	  
more	  similar	  to	  white	  blood	  cells,	  which	  do	  not	  have	  cell	  walls.	  It	  is	  impossible	  to	  know	  what	  
compounding	  effects	  the	  yeast	  cell	  wall	  may	  be	  having	  on	  the	  assay.	  
We	  were	  able	  to	  develop	  a	  dependable	  assay	  for	  the	  effect	  of	  clozapine	  on	  yeast	  cell	  growth.	  This	  
assay	  was	  successfully	  repeated	  11	  times,	  in	  which	  each	  time	  both	  duplicates	  showed	  normal	  growth	  
without	  clozapine	  and	  inhibited	  growth	  after	  12	  hours	  in	  the	  presence	  of	  clozapine	  and	  H2O2.	  Future	  
experiments	  attempting	  to	  elucidate	  the	  mechanism	  of	  clozapine-­‐induced	  agranulocytosis	  using	  yeast	  as	  
a	  model	  system,	  such	  as	  future	  S.	  cerevisiae	  genomic	  screens,	  will	  surely	  find	  this	  assay	  valuable.	  This	  
study	  could	  only	  estimate	  the	  MIC50	  of	  clozapine	  for	  yeast	  cells	  to	  be	  between	  5	  and	  10	  µM.	  To	  
determine	  the	  exact	  MIC50	  a	  range	  of	  concentrations	  of	  clozapine,	  between	  5	  and	  10	  µM,	  should	  be	  
tested	  to	  focus	  the	  study.	  This	  will	  also	  give	  investigators	  a	  better	  understanding	  of	  what	  concentrations	  
of	  clozapine	  with	  which	  to	  conduct	  the	  genomic	  screens	  in	  order	  to	  identify	  resistant	  and	  sensitive	  
mutants.	  Future	  experiments	  should	  be	  done	  to	  further	  narrow	  the	  range	  of	  concentrations	  of	  clozapine	  
that	  account	  for	  the	  MIC50.	  	  
Finally,	  clozapine-­‐induced	  cell	  growth	  inhibition	  was	  apparent	  only	  in	  the	  presence	  of	  H2O2	  
indicating	  that	  H2O2	  is	  necessary	  for	  clozapine	  to	  inhibit	  cell	  growth.	  In	  the	  control	  group	  of	  reaction	  
mixtures	  containing	  no	  H2O2,	  there	  was	  no	  inhibition	  of	  cell	  growth	  even	  at	  the	  highest	  concentration	  of	  
clozapine.	  This	  is	  a	  significant	  observation,	  because	  we	  hypothesize	  that	  granulocytes	  produce	  H2O2	  
upon	  endocytosis	  of	  clozapine.	  The	  data	  supports	  our	  hypothesis	  of	  an	  immune	  dependent	  mechanism	  
of	  action	  for	  clozapine-­‐induced	  agranulocytosis.	  	  Further	  study	  will	  establish	  the	  exact	  nature	  of	  the	  
interaction	  between	  clozapine	  and	  yeast	  and	  whether	  the	  interaction	  between	  clozapine	  and	  white	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